<DOC>
	<DOCNO>NCT00903851</DOCNO>
	<brief_summary>Patients Type I II diabetes painful distal symmetric sensorimotor polyneuropathy dynamic allodynia low extremity , patient Type I II diabetes pain distal symmetric sensorimotor polyneuropathy dynamic allodynia low extremity , patient idiopathic distal predominantly sensory neuropathy participate Phase IV clinical trial ass efficacy lidocaine patch treat painful diabetic neuropathy idiopathic distal sensory neuropathy .</brief_summary>
	<brief_title>LidodermÂ® ( Lidocaine Patch 5 % ) Diabetic Idiopathic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Lidocaine</mesh_term>
	<criteria>At Sites 1 , 2 , 3 Had painful diabetic polyneuropathy 3 month duration At Site 1 Had clinical sign symptom distal predominantly sensory polyneuropathy 3 month duration . Diagnosis predominantly sensory polyneuropathy confirm either nerve conduction study ( large fiber sensory sensorimotor axonal neuropathy ) abnormal epidermal innervation punch skin biopsy ( distal leg/proximal thigh ) ( Herrmann et al. , 1999 ; Holland et al. , 1997 ) Had average daily pain rating baseline week pain rating equal 4 great 0 10 numerical pain rating scale Had least 2 hour moderate severe pain intensity due polyneuropathy daily immediately prior 3month period Were use stable analgesic drug therapy least 1 week ( regimen dosage ) prior screen visit , exception acetaminophen lidocaine patient undergo punch skin biopsy Had prior treatment topical lidocaine , except use punch skin biopsy procedure Were currently treatment Class I antiarrhythmic agent ( tocainide mexiletine ) Had pain severe painful diabetic idiopathic neuropathy Had open skin lesion area lidocaine patch apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>